BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved kidney failure drug to market as a potential treatment for liver disease. | BioVie is eyeing a ...
Desmoda (desmopressin acetate) Vasopressin 2 receptor agonist Management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. FDA Approves Desmoda Oral ...
Although tolvaptan bests fluid restriction at raising plasma sodium concentration, 19% of patients experience overcorrection ...
In sum, the nonapeptide Oxytocin presents as a structurally well-defined peptide with a receptor system that is widely ...
Clinicians now have an FDA-approved liquid desmopressin option for central diabetes insipidus, designed for dosing consistency across the age spectrum.
Retex Pharmaceuticals Inc. has patented vasopressin V2 receptor antagonists potentially useful for the treatment of hyponatremia, cardiovascular disorders, autosomal dominant and autosomal recessive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results